EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Impact of Frontline Systemic Treatment Choice on Clinical Outcome in Advanced Leiomyosarcoma: A CanSaRCC Study

Erica C Koch Hein, Abha Gupta, Hagit Peretz Soroka, Caroline Holloway iD, Brookelyn Biffart, Carolyn Nessim, Tristan Wild, Katherine Lajkosz, Geoffrey A Watson, Albiruni Abdul Razak, Abdulazeez Salawu iD

Cancer Medicine · 2026-07 · 15 (7)

DOI: 10.1002/cam4.72080 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 14.07.2026. Verfasst von Erica C Koch Hein und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Princess Margaret Cancer Centre and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leiomyosarcoma, Uterine Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Frontline systemic treatment selection for advanced leiomyosarcoma (LMS) remains variable in routine practice. Gemcitabine‐based regimens are frequently used despite randomized evidence of non‐superiority compared with doxorubicin‐based regimens and greater complexity in treatment delivery.

Methods

This multi‐centre retrospective cohort study included advanced/metastatic LMS patients treated with frontline doxorubicin‐ or gemcitabine‐based chemotherapy at four Canadian sarcoma centres (2010–2022). The primary endpoint was overall survival (OS). Secondary endpoints were time to second‐line treatment (T2T) and number of subsequent systemic treatment lines. Subgroup analyses were conducted by primary tumor site (uterine vs. non‐uterine LMS).

Results

Among 217 patients, median OS was 17.1 months (95% CI 14.8–21.1). OS did not differ between frontline doxorubicin‐ and gemcitabine‐based regimens (17.8 vs. 16.1 months; p = 0.16), nor did T2T (5.8 vs. 6.3 months; p = 0.77). Non‐uterine primary site and surgery following frontline systemic treatment were independently associated with improved OS. Median OS was longer for non‐uterine versus uterine LMS (23 vs. 12.8 months; p < 0.001).

Conclusions

In this large real‐world LMS cohort, outcomes were not influenced by frontline chemotherapy choice. These findings support prioritizing toxicity, quality of life, cost, and treatment delivery burden when selecting frontline therapy, particularly where doxorubicin/trabectedin use is limited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLeiomyosarcomaUterine NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedCanadaDeoxycytidineDoxorubicinGemcitabineRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

chemotherapydoxorubicingemcitabineleiomyosarcoma

Substanzen

DeoxycytidineDoxorubicinGemcitabine

Autor:innen und Institutionen

  • Division of Medical Oncology, Princess Margaret Cancer Centre and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada.
  • Division of Radiation Oncology, BC Cancer, University of British Columbia, Victoria, British Columbia, Canada.
  • Department of Surgery, The Ottawa Hospital and Research Institute, University of Ottawa, Ottawa, Canada.
  • Department of Biostatistics, University Health Network, Toronto, Canada.

ORCID-Profile: Caroline Holloway, Abdulazeez Salawu

Zitieren

APA

Hein, E. C. K., Gupta, A., Soroka, H. P., Holloway, C., Biffart, B., Nessim, C., Wild, T., Lajkosz, K., Watson, G. A., Razak, A. A., & Salawu, A. (2026). Impact of Frontline Systemic Treatment Choice on Clinical Outcome in Advanced Leiomyosarcoma: A CanSaRCC Study. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72080

Vancouver

Hein ECK, Gupta A, Soroka HP, Holloway C, Biffart B, Nessim C, et al. Impact of Frontline Systemic Treatment Choice on Clinical Outcome in Advanced Leiomyosarcoma: A CanSaRCC Study. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72080

BibTeX
@article{Hein2026,
  author = {Hein, Erica C Koch and Gupta, Abha and Soroka, Hagit Peretz and Holloway, Caroline and Biffart, Brookelyn and Nessim, Carolyn and Wild, Tristan and Lajkosz, Katherine and Watson, Geoffrey A and Razak, Albiruni Abdul and Salawu, Abdulazeez},
  title = {Impact of Frontline Systemic Treatment Choice on Clinical Outcome in Advanced Leiomyosarcoma: A CanSaRCC Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cam4.72080}
}
Kostenlos starten →